PMID- 21760531
OWN - NLM
STAT- MEDLINE
DCOM- 20111228
LR  - 20221207
IS  - 1537-4513 (Electronic)
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 34
IP  - 7
DP  - 2011 Sep
TI  - Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized 
      by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.
PG  - 525-34
LID - 10.1097/CJI.0b013e318226bd45 [doi]
AB  - CD4 T lymphocytes play a central role in orchestrating an efficient antitumor 
      immune response. Much effort has been devoted in the identification of major 
      histocompatibility complex class II eptiopes from different tumor-associated 
      antigens. Melan-A/MART-1 is expressed specifically in normal melanocytes and 
      tumor cells of 75% to 100% of melanoma patients. Melan-A/MART-1 is considered as 
      an attractive target for cancer immunotherapy. In the past, several human 
      leukocyte antigen (HLA) class II restricted epitopes have been identified and 
      characterized, including Melan-A/MART-11-20 (HLA-DR11 restricted), 
      Melan-A/MART-125-36 (HLA-DQ6 and HLA-DR3 restricted), Melan-A/MART-127-40 
      (HLA-DR1 restricted), Melan-A/MART-151-73 (HLA-DR4 restricted), 
      Melan-A/MART-191-110 (HLA-DR52 restricted), and Melan-A/MART-1100-111 (HLA-DR1 
      restricted). Owing to the infrequent expression of the above HLA class II alleles 
      in Asian populations, immunotherapy using these defined Melan-A/MART-1 peptides 
      could potentially only benefit a very small percentage of Asian melanoma 
      patients. In this study, we established several CD4 T-cell clones by in vitro 
      stimulation of peripheral blood mononuclear cells from a healthy donor by a 
      peptide pool of 28 to 30 amino acid long peptides spanning the entire 
      Melan-A/MART-1 protein. These CD4 T-cell clones recognized a peptide that is 
      embedded within Melan-A/MART-121-50, in a HLA-DPB1*0501 restricted manner. 
      Finally, we demonstrated that this epitope is naturally processed and presented 
      by dendritic cells. HLA-DPB1*0501 is frequently expressed in Asian population 
      (44.9% to 73.1%). Therefore, this epitope could provide a new tool and could 
      significantly increase the percentage of melanoma patients that can benefit from 
      cancer immunotherapy.
FAU - Meng, Zhaoting
AU  - Meng Z
AD  - Department of Medical Oncology, PLA General Hospital Beijing, China.
FAU - Wang, Yadong
AU  - Wang Y
FAU - Zhang, Guanzhong
AU  - Zhang G
FAU - Ke, Yuehua
AU  - Ke Y
FAU - Yan, Yanfeng
AU  - Yan Y
FAU - Wu, Liangliang
AU  - Wu L
FAU - Huang, Qianrong
AU  - Huang Q
FAU - Zeng, Gang
AU  - Zeng G
FAU - Wang, Yu
AU  - Wang Y
FAU - Ying, Han
AU  - Ying H
FAU - Jiao, Shunchang
AU  - Jiao S
LA  - eng
GR  - R03 CA128086/CA/NCI NIH HHS/United States
GR  - R03 CA128086-02/CA/NCI NIH HHS/United States
GR  - R21 CA137651/CA/NCI NIH HHS/United States
GR  - R21 CA137651-01A1/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-DP beta-Chains)
RN  - 0 (HLA-DPB1*05:01 antigen)
RN  - 0 (MART-1 Antigen)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Asian People
MH  - CD4-Positive T-Lymphocytes/*immunology/metabolism
MH  - Cell Line, Tumor
MH  - Dendritic Cells/*immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Epitopes, T-Lymphocyte/*immunology
MH  - HLA-DP beta-Chains/*immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunotherapy
MH  - MART-1 Antigen/*biosynthesis/*immunology
MH  - Melanocytes/metabolism
MH  - Melanoma/immunology/metabolism
MH  - T-Lymphocytes, Cytotoxic/immunology/metabolism
PMC - PMC4426979
MID - NIHMS366353
COIS- All authors have declared there are no conflicts of interest with regards to this 
      study.
EDAT- 2011/07/16 06:00
MHDA- 2011/12/29 06:00
PMCR- 2015/05/11
CRDT- 2011/07/16 06:00
PHST- 2011/07/16 06:00 [entrez]
PHST- 2011/07/16 06:00 [pubmed]
PHST- 2011/12/29 06:00 [medline]
PHST- 2015/05/11 00:00 [pmc-release]
AID - 10.1097/CJI.0b013e318226bd45 [doi]
PST - ppublish
SO  - J Immunother. 2011 Sep;34(7):525-34. doi: 10.1097/CJI.0b013e318226bd45.